Melanie Golliver, APRN
Family · Pocahontas, ARNPI 1043979024
Payments from drug & device makers
Across 156 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$838
- Novo Nordisk$514
- Amgen$398
- Bayer$265
- Lilly USA, LLC$178
- GSK$69
- plus $503 from 15 others
What the payments were for
- Food & beverage$2,766100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $838 |
| Novo Nordisk | 34 | $514 |
| Amgen | 29 | $398 |
| Bayer | 13 | $265 |
| Lilly USA, LLC | 15 | $178 |
| GSK | 4 | $69 |
| Novartis | 5 | $69 |
| Corcept Therapeutics | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 4 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| AbbVie | 2 | $31 |
| Exact Sciences | 2 | $30 |
| Lundbeck LLC | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Merck | 1 | $16 |
| Pfizer | 1 | $15 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,766 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $84,855 |
| EliquisApixaban | 47 | $35,968 |
| JardianceEmpagliflozin | 47 | $33,999 |
| MounjaroTirzepatide | 31 | $33,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,222 |
| FarxigaDapagliflozin Propanediol | 29 | $19,769 |
| JanuviaSitagliptin Phosphate | 19 | $13,833 |
| RybelsusSemaglutide | 11 | $13,242 |
| TrulicityDulaglutide | 12 | $11,071 |
| MyrbetriqMirabegron | 18 | $9,506 |
| LinzessLinaclotide | 13 | $7,955 |
| EntrestoSacubitril/Valsartan | 14 | $7,889 |
| TradjentaLinagliptin | 11 | $7,038 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,771 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $2,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $514 | $98,09790 claims |
| Lilly USA, LLCMounjaro, Trulicity | $178 | $44,62743 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $37,99352 claims |
| PfizerEliquis | $15 | $35,96847 claims |
| AstraZenecaFarxiga | $838 | $19,76929 claims |
| MerckJanuvia | $16 | $13,83319 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $9,50618 claims |
| AbbVieLinzess | $31 | $7,95513 claims |
| NovartisEntresto | $69 | $7,88914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.
Other family in Pocahontas
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.